Questions and responses 41st Parliament, 1st session June 2, 2011, to September 13, 2013

Refine your search

Search results for topic:"Multiple sclerosis"

Results from historical information do not include searching within the departmental responses.
Historical information
The information shown below relates to a prior session.

Q-12

41-1
June 2, 2011, to September 13, 2013

Q-12

41st Parliament, 1st session
Asked by
Date asked
June 6, 2011
Answered
September 19, 2011
With respect to chronic cerebrospinal venous insufficiency (CCSVI), the liberation treatment, and multiple sclerosis (MS): (a) what consensus documents have been published regarding the diagnosis and treatment of CCSVI, (i) by whom, (ii) on what dates, (iii) what were the recommendations, (iv) were they reviewed by the August 26, 2010, meeting of the CIHR in collaboration with the Multiple Sclerosis Society of Canada (MSSC); (b) why were Canadian members of the International Union of Phlebology (IUP), who were part of the consensus process regarding the diagnosis and treatment of CCSVI, not consulted during the August 26 meeting of the Canadian Institutes of Health Research (CIHR); (c) what are the details of any plan the government has or is developing to collect evidence regarding the diagnosis and treatment of CCSVI, for example, through clinical trials or the creation of a registry; (d) what percentage of surgical procedures in Canada have been double-blind tested over the last 40 years and, for this percentage, (i) what is the risk of complication, (ii) what is considered an acceptable risk of complication, (iii) how do physicians judge acceptable risk and convey this risk to their patients, (iv) what actions do physicians take to reduce risk if the patient chooses to undertake the procedure; (e) when a medical treatment appears to be potentially effective, is its approval ever fast-tracked by the relevant Canadian authorities and, if so, (i) what are any examples of this in Canada over the last five years, (ii) has this ever happened with respect to MS, (iii) if so, who advocated for a fast-tracking and when, (iv) what process was followed to allow the treatment, (v) who made the decision to proceed, (vi) why was fast-tracking deemed necessary, (vii) what were the known risks at the time of the request, (viii) what, if any, negative impacts resulted; (f) what are the reasons for the length of time it has taken the relevant Canadian authorities to implement clinical trials or to develop a registry; (g) why did no member of the August 26 group declare any conflicts of interest, either real or perceived; (h) how many liberation procedures did the August 26 group estimate have been undertaken, (i) which countries were undertaking the procedure, (ii) to which countries were Canadians travelling, (iii) were the practitioners considered to be sufficiently trained, (iv) were the procedures in these countries found to be safe; (i) which people, labs and operating theatres had undertaken the diagnosis or treatment of CCSVI in Canada prior to the August 26 meeting; (j) why did the August 26 meeting not include Canadian experts in the imaging or treatment of CCSVI and for what reasons was Dr. Sandy McDonald not included as a participant; (k) why did the August 26 meeting not include international experts in diagnosis and treatment of CCSVI, data presented at international scientific conferences or site visits to labs and operating theatres, which were or had been undertaking diagnosis or treatment; (l) what is a comprehensive explanation of why the inclusion of CCSVI and liberation experts might have biased the sample of the August 26 group and whether such selection is an established practice at all CIHR meetings; (m) what are all the names of the group members who had spoken out against diagnosis or treatment of CCSVI or the liberation procedure prior to the August 26 meeting, what were the details of their positions, and what are their publically-available comments on the matter; (n) who were all the members of the August 26 group and, for each member, what were his or her stated or declared conflicts of interest or perceived conflicts of interest; (o) what was the August 26 group’s assessment of and comments concerning all reviewed published papers, including both positive and negative observations; (p) did the August 26 group find it unusual that two of the reviewed papers had been accepted for publication in only six weeks, (i) did the group review whether this is a common practice in medicine, (ii) did the group consider how and why this might happen, (iii) did the group explore the expertise of those writing the papers, their experience, how their results compared with those of Dr.Zamboni and, if so, (iv) what were the group's findings for questions posed in (iii); (q) which neurologists, present at the August 26 meeting, had followed MS patients who were diagnosed with CCSVI and who had been treated for the condition, (i) how had neurologists followed them (e.g., appointment, EDSS score/another scale, MRI, neurological exam, etc.), (ii) what, if any, evidence did they present of patients' progress following the liberation procedure; (r) did the August 26 group find the reversal in the MSSC's position, who was part of the greater group, unusual, (i) did the group investigate or consider the reasons for this change in position and, if so, (ii) what observations did it make or conclusions did it come to regarding the reversal; (s) did the August 26 group estimate how its decision might impact Canadian MS patients, including (i) impacts on their mental health and how this might impact their disease, (ii) the number of Canadian MS patients who might feel forced to seek help outside Canada, (iii) how air travel, a compromised vascular system, recent surgery, and lack of follow-up in Canada might impact their disease and, if so, (iv) what are the results of those estimations; (t) what consensus documents are forthcoming, (i) by whom, (ii) when will they be published; (u) what is the work plan for the new expert working group which met for the first time on November 23, 2010, (i) who are the panellists, what are their qualifications and what is their expertise in diagnosis and treatment of CCSVI, (ii) how were the panellists chosen and by whom, (iii) what is the group’s mandate and how was it derived, (iv) what is the schedule of meetings, (v) what is the timeline for the group’s work, (vi) what evidence will be reviewed to reach any decision about possible clinical trials, registry, diagnosis, treatment, follow-up care, etc.; (v) what was the agenda for the November 23 meeting of the expert working group, (i) what abstracts, documents, and presentations were reviewed, (ii) which Canadian and international experts, with experience in diagnosis and treatment of CCSVI, were consulted, (iii) what Canadian and international unpublished data were explored, (iv) what Canadian and international labs or operating theatres were reviewed and visited; (w) for what reasons is the new group going to analyze interim and final results from seven studies funded by the Canadian and US MS Societies and why are these studies considered more worthwhile cases for analysis than other studies already completed; (x) when will the November 23 expert panel declare and post any conflicts of interest, following the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) guide, on the CIHR website to eliminate the possibility of real or perceived conflicts; and (y) further to assurances made by the President of CIHR, Dr. Alain Beaudet, to the Subcommittee on Neurological Diseases on December 7, 2010, that MS patients who have had the liberation procedure would have follow-up, what are the details of how that follow-up will occur, specifically, (i) how will “a message be sent”, by whom, to whom, by when and what will the message be, (ii) specifically, will all patients who travel or travelled outside Canada be assured that their doctors will see them, that appointments will not be cancelled, that tests will not be cancelled, that they will have access to recommended prescriptions, that they will not lose their long-term care and that they will not be berated for making the decision to have liberation, (iii) how will this be enforced, (iv) what action should MS patients take if they are denied care, (v) to whom should they report a denial of care, (vi) what are the consequences for a physician or health practitioner or organization who delivers care but fails to provide follow-up care, (vii) will follow-up include ultrasound or MRI to image the veins of MS patients and, if so, how often will these imaging procedures occur and who will pay for them?
Historical information
The information shown below relates to a prior session.

Q-731

41-1
June 2, 2011, to September 13, 2013

Q-731

41st Parliament, 1st session
Asked by
Date asked
June 12, 2012
Answered
September 17, 2012
With respect to the multiple sclerosis (MS) drugs, Tysabri and Gilenya: (a) before these drugs were approved for use in Canada, (i) what detailed processes were undertaken to ensure safety, efficacy and quality, (ii) how many drugs have been reviewed, (iii) how has the review process been resolved, including, but not limited to, (iv) how many drugs have been pulled from the market, (v) how many drugs have been given new prescription criteria, (vi) how many drugs have been put back on the market; (b) for the phase I clinical trial for each drug, (i) when (start month and year to end month and year) and where (company/research facility and country) did they take place, (ii) how many MS patients were enrolled for each trial, (iii) for each trial, how many controls were used, (iv) for each trial, which variables were controlled, (v) which medical specialists monitored the patients during each trial and afterward, (vi) how was a safe dosage determined for each drug, (vii) what was the safe dosage range for each drug, (viii) what side effects were identified for each drug, (ix) why was it decided to move ahead to a phase ll trial for each drug; (c) what, if any, other information was reviewed beyond the phase I trial for each drug; (d) for the phase II clinical trial for each drug, (i) when (start month and year to end month and year) and where (company/research facility and country) did they take place for each drug, (ii) how many MS patients were enrolled for each trial, (iii) for each trial, how many controls were used, (iv) for each trial, what variables were controlled, (v) which medical specialists monitored the patients during each trial and afterward, (vi) what was the safe dosage range for each drug, (vii) what evidence was there that each drug was safe, (viii) what evidence was there that each drug was effective, (ix) why was it decided to move ahead to a phase llI trial for each of the drugs; (e) what, if any, other information was reviewed beyond the phase II trial for each drug; (f) for the phase III clinical trial for each drug, (i) when (start month and year to end month and year) and where (company/research facility and country) did they take place for each drug, (ii) for each trial, how many MS patients were enrolled, (iii) for each trial, how many controls were used, (iv) for each trial, what variables were controlled, (v) which medical specialists monitored the patients during each trial and afterward, (vi) what was the safe dosage range for each drug, (vii) what evidence was there that each drug was safe, (viii) what evidence was there that each drug was effective, (ix) what side effects were identified for each drug, (x) how did the two drugs compare to commonly used treatments, (xi) what information was collected that would allow the two drugs to be used safely, (xii) why was it was decided to move ahead to market both drugs; (g) what, if any, other information was reviewed beyond the phase III trial for each of the drugs; (h) Tysabri was known to cause progressive multifocal leukoencephalopathy (PML), a rare brain disorder that usually causes death or severe disability, (i) what was the benefit/risk profile for the drug, (ii) why did Health Canada choose to fast-track the drug, (iii) did the MS Society of Canada support the fast-tracking of Tysabri, (iv) why did Health Canada not make monitoring mandatory, as was done in the United States, (v) was the decision regarding monitoring ever changed and, if so, when, (vi) how do 252 confirmed cases of PML and 52 deaths fit with Health Canada’s benefit/risk profile; (i) Gilenya was known to slow a patient’s heart rate down, especially after the first dose, but the heart rate usually returned to normal within one month, (i) what was the benefit/risk profile for the drug, (ii) did anyone die during clinical trials and, if so, how many people, (iii) what evidence was provided regarding the source of deaths, (iv) how was risk assessed; (j) based on the information in (i), was there any group identified who should not take the drug, (i) particularly those with cardiovascular and/or cerebrovascular disease; (k) what percentage of MS patients have cardiovascular and/or cerebrovascular disease, and (i) when did the information in (k) become known; (l) were Canadian physicians involved in the phase I to III clinical trials for Tysabri/Gilenya and, if so, (i) did they receive financial assistance from Biogen Idec or Novartis, (ii) did they provide support or recommendation for either of the drugs to the government, (iii) did they ever serve on any expert panel to the government regarding MS; (m) what assistance has Biogen Idec and Novartis provided to the MS Society of Canada or any of the Society’s funded scientists, (i) was there an involvement from the MS Society of Canada in the phase I to III clinical trials for Tysabri and Gilenya and, if so, (ii) did they receive any financial assistance from Biogen Idec and Novartis, (iii) did the Society or any of its board members, scientists or other members provide any support or recommendation for the drugs to the government, (iv) did the Society or any of its board members, scientists or other members serve on any expert panel to the government regarding MS; (n) what phase IV clinical trials have been undertaken for drugs in (i) Canada and by whom, and (ii) internationally; (o) when were the drugs first marketed in Canada, (i) when were the drugs first available in Canada, (ii) when were problems or signals first identified for each drug in Canada and internationally; (p) what do adverse reaction reports in Canada and internationally show for each drug, and what is the (i) Canadian and (ii) international data for each drug; (q) which countries have placed either of the two drugs under review, and for each drug, identify the start date of the review for each country; (r) did Health Canada put Gilenya under review on February 28 2012, as a result of (i) the identification of safety concerns, (ii) the establishment of causal relationships, (iii) serious adverse events, including 11 deaths reported internationally, or (iv) other reasons, and, if so, identify the reasons; (s) for what reasons is the continued prescribing of Gilenya permitted despite the incidence of deaths internationally, and have any further deaths occurred since the drug has been under review; (t) what, if any, monitoring takes place to ensure that healthcare professionals are following the Health Canada advisory urging them to continue to follow Gilenya’s labelling instructions closely, particularly with respect to patient monitoring; (u) while Gilenya has been under review in Canada, have other medical agencies internationally provided any additional evidence and warnings, and, if so, what are the details, including whether Canada has followed suit; (v) what are the details of all actions taken by Health Canada to monitor the safety of Tysabri and Gilenya while the drugs have been on the market, including (i) adverse reaction reports in Canada and internationally, (ii) post-market studies, (iii) published data, (iv) international safety data, (v) collaboration with international counterparts; (w) what are the details of all information about Tysabri and Gilenya that has been obtained by Health Canada through (i) adverse reaction reports in Canada and internationally, (ii) post-market studies, (iii) published data, (iv) international safety data, (v) collaboration with international counterparts; (x) what, if any, collaboration takes place between Health Canada and Biogen Idec and Novartis to ensure that the safety profile of the drugs is monitored on an ongoing basis; (y) what are the details of the drug review process in the case of Gilenya, including (i) start and end date, (ii) Canadian and international information to be reviewed, (iii) reviewers, (iv) international partners, (v) benefit/risk profiles and thresholds, (vi) milestones, (vii) other relevant information; (z) what timeline does the government’s policy provide to communicate any new safety information that may arise concerning Gilenya; and (aa) what actions does Health Canada plan to take following the review of Gilenya?
Historical information
The information shown below relates to a prior session.

Q-142

41-1
June 2, 2011, to September 13, 2013

Q-142

41st Parliament, 1st session
Asked by
Date asked
September 19, 2011
Answered
November 3, 2011
With respect to the venous system, and more particularly, chronic cerebrospinal venous insufficiency (CCSVI): (a) what, if any, steps is the government taking to address research questions regarding the venous system, including (i) what does the normal venous system look like, and, specifically, what does it look like in infants, children, and adults, (ii) can the veins, in particular the jugulars and the azygous, look normal, and the flow be abnormal, (iii) what is the normal range of flow through veins, in particular the jugulars and the azygous, (iv) how should normal range of flow through veins, in particular the jugulars and azygous, be defined, (v) what is the normal range of blood gases in veins, in particular the jugulars and the azygous, (vi) what causes venous pathology and when does it occur, (vii) theoretically, what is the complete range of possible vascular problems in the head, neck, chest, and spine, which ones might impact health, and specifically which ones might be linked to multiple sclerosis (MS), (viii) how does the complete range of possible vascular problems compare with those actually seen in patients, (ix) how should abnormal flow through veins, in particular the jugulars and the azygous, be defined, (x) how might abnormal blood gases in veins affect health in the short-term and long-term, (xi) what, if any, reflux is normal in veins, and, if some reflux is normal, what is the ‘tipping point’ to abnormal, (xii) can a catalogue of venous pathology (in the head, neck, chest and spine), abnormal flow, and potential health impacts be established, (xiii) what protects against abnormal venous pathology and abnormal flow, (xiv) who should receive venous protective measures, and when should protective measures be put in place; (b) what, if any, steps is the government taking to address research questions regarding the venous system and MS, including, (i) can fluid mechanics predict where physiologic changes in the brain might occur, (ii) how does the neurologist’s understanding of flow through the brain compare with that of physicists, (iii) does decreased metabolism lead to hypoxia which may lead to endothelial damage and inflammation, (iv) what occurs first, inflammatory changes in the brain or iron deposition, (v) what role does reduced perfusion have in MS, (vi) does stenosis extra-cranially cause less perfusion in the brain, (vii) does stenosis extra-cranially cause morphological changes in the brain, (viii) do cerebral veins actually disappear over time, or is it merely a lack of flow that makes them look like they disappear in magnetic resonance imaging (MRI) studies; (ix) what, if any changes beyond lesions, occur in the spinal cord of MS patients, as a result of reduced vertebral flow, (x) do vertebral veins show a similar disappearance over time, (xi) what percentage of MS patients show evidence of venous pathology, as compared to 'normals', (xii) what other venous abnormalities might MS patients have (e.g., bladder, intestine, kidney), might these abnormalities play a role in their disease, and, if so, how should they be imaged and treated, (xiii) what percentage of MS patients show venous abnormalities below the chest (e.g., May Thurner syndrome), and does this have an impact on their disease, (xiv) how does the vascular system of someone with benign MS compare to that of someone with relapsing-remitting, primary progressive or secondary progressive MS; (c) what, if any, steps is the government taking to address research questions regarding CCSVI and MS, including, (i) what is the prevalence of CCSVI in relapsing-remitting, primary progressive or secondary progressive MS, (ii) does CCSVI worsen over time with the progression of disease, (iii) does CCSVI play a role in MS, and, if so, how, (iv) is CCSVI specific to MS, (v) what are the potential health impacts of CCSVI in the short-term, medium-term and long-term, both with and without treatment; (d) what, if any, steps is the government taking to address research questions regarding CCSVI diagnosis, including (i) how do the results of MRI compare with those of ultrasound for diagnosis of CCSVI, (ii) what is the best way to image the venous system and the best way to image venous pathology, (iii) what are the limitations of current diagnostic tools to image the venous system, (iv) should intravascular ultrasound be used, and what are the benefits and the risks, (v) what is the learning curve for the various diagnostic procedures, and what should practitioners undertake to become sufficiently accomplished, (vi) can a standardized protocol be established for diagnosing CCSVI in MS patients, and when should MS patients be tested for CCSVI, (vii) can a standardized system for describing lesions (e.g., type, location) be established, (viii) what should be the decision-making process regarding whether to treat or not to treat (e.g., anatomy, flow, etc.), (ix) should arterial, venous and CSF flow be monitored, how often, and for what purpose, (x) should lesions and iron load be monitored, how often, and for what purpose; (e) what, if any, steps is the government taking to address research questions regarding CCSVI treatment, including (i) what timescale is useful for treatment of CCSVI, (ii) what are the benefits and risks associated with treatment of CCSVI, (iii) what are best practices for treating each identified vascular problem, (iv) how should a successful CCSVI treatment be defined (e.g., valvular correction, reduction in stenosis, increased flow, improved blood gases), (v) can malformed jugulars and azygous be treated to achieve normal flow, (vi) can malformed jugulars and azygous be treated to achieve a normal range of blood gases, (vii) can jugulars and azygous be sufficiently treated to make up for poor vertebral flow, and, if not, what procedures can be developed to improve vertebral flow, (viii) should stents be used, and, if so, under what circumstances, (ix) what are the immediate complications of CCSVI treatment, and in what percentage of treatments does each occur for each identified abnormality, (x) what is the best follow-up anti-coagulant therapy, what are the potential risks, and what is the prevalence of complications, (xi) what are the best follow-up therapies, including, brain plasticity exercises, nutrition, physiotherapy, speech therapy, etc., and which therapies have the best associated outcomes, (xii) what are late complications, what follow-up is necessary to determine late complications, and in what percentage of treatments does each occur for each identified abnormality, (xiii) what treatments are available should a stent be occluded, either through hyperplasia or thrombosis, (xiv) what is the success rate of each identified treatment for an occluded stent; (f) what, if any, steps is the government taking to address research questions regarding determining the best CCSVI treatment, including, (i) is CCSVI treatment with the addition of pharmacological agents more efficacious than just the CCSVI procedure, (ii) what pharmacological agents could be used to treat venous inflammation, iron storage, and hydrocephaly, and could these agents be added to CCSVI treatment, (iii) what safe apparatuses could be developed to keep treated veins open, (iv) are vein grafts possible, and if so, on whom, and when should they be used, (v) is CCSVI treatment more efficacious with mesenchymal-derived or adipose-derived stem-cell infusion than just the CCSVI procedure alone, (vi) what methods might be added to reduce permeability of the blood-brain barrier, including pharmacological agents and stem cells, (vii) what are the effects of chelators on iron uptake and release from the brain, and might iron chelators be used as therapeutic agents; (g) what, if any, steps is the government taking to address research questions regarding possible impacts of CCSVI treatment on MS patients, including (i) what impact does CCSVI treatment have on patients immediately, (ii) what impact does CCSVI treatment have on patients at 24 hours, 3 months, 6 months, 1 year, and 2 years, (iii) what does the magnetic resonance venography (MRV) of a treated patient look like at 24 hours, 3 months, 6 months, 1 year, and 2 years, (iv) what percentage of MS patients show functional improvement at 3 months, 6 months, 1 year, and 2 years, (v) what are the most appropriate scales to measure any health impacts following CCSVI treatment as reported by MS patients, (vi) do new scales have to be created to measure reported changes following treatment, (vii) which patients show the greatest improvement, and does early intervention allow for a better outcome, (viii) what are the treatment outcomes associated with each of the identified venous problems, (ix) what percentage of MS patients show a reduction in MS attacks and brain lesions following the CCSVI procedure, (x) what percentage of MS patients with little or mild blockage show improvement following the CCSVI procedure, (xi) for those MS patients whose conditions do not improve or become worse, why does this occur; (h) what, if any, steps is the government taking to address research questions regarding CCSVI re-stenosis and diagnosis, including, (i) what is rate of stenosis for each identified vascular abnormality, (ii) what changes should patients be told to look for to in order to recognize whether they are possibly re-stenosing, (iii) what diagnostic methods should be used after treatment for CCSVI, (iv) what diagnostic methods should be used to look for re-stenosis, and at what timescales; (i) what, if any, steps is the government taking to address research questions regarding secondary procedures for CCSVI, including, (i) are secondary procedures safe, and if so, how many, (ii) what should be the follow-up protocol for secondary procedures, (iii) should there be a methodology established regarding whether to do a secondary procedure or not; and (j) what, if any, steps is the government taking to address research questions regarding prevention in the next generation, including, (i) do vascular issues develop in utero, during childhood, or later, and what would be the best methods to discover circulation problems at the earliest time possible to avoid health impacts at a later date, (ii) might vascular birthmarks and tumours be an indication of potential vascular problems, (iii) might skin discolouration, skin abnormalities, and even proliferation of moles be an indication of an autoimmune or neural condition, (iv) might giving vitamin D to pregnant mothers reduce the risk of children being born with, or developing, vascular problems and other conditions and, if so, what dosage is appropriate, (v) do antioxidants, vitamin D and omega 3 reduce vein inflammation, (vi) will giving children and adolescents vitamin D reduce the risk of developing vein inflammation and venous hypertension and, if so, what dosage is appropriate, and what quantity should be recommended for a child with a family history of CCSVI, vascular problems or MS, etc., (vii) what would be the optimum time to undertake CCSVI treatment to avoid health impacts at a later date?
Historical information
The information shown below relates to a prior session.

Q-10

41-1
June 2, 2011, to September 13, 2013

Q-10

41st Parliament, 1st session
Asked by
Date asked
June 6, 2011
Answered
September 19, 2011
With respect to the full process currently being undertaken by the Canadian Institutes of Health Research (CIHR) regarding chronic cerebrospinal venous insufficiency (CCSVI), including the August 26, 2010, meeting of the Scientific Expert Working Group (SEWG) and the CIHR’s “knowledge synthesis review”: (a) what is the accepted operating definition of “conflict of interest” for the CIHR, (i) why was no disclosure statement made by all participants who attended the August 26, 2010, joint meeting of the CIHR and the Multiple Sclerosis Society of Canada (MSSC), (ii) are there plans to provide an opportunity to declare possible conflicts of interest subsequent to the meeting; (b) what are the details of all information produced and circulated by the CIHR in January 2011 regarding follow-up care for multiple sclerosis (MS) patients and to which organizations was the information sent; (c) will the disclosure statement to be signed by members of the SEWG at its next meeting in June 2011 include specific reference to any (i) consultancy, (ii) grant support, (iii) membership on advisory councils, (iv) speaker’s bureau, (v) other sources of funding a member might have; (d) how does the CIHR plan to ensure that all members of the SEWG have the same understanding of private or personal interests that could influence decision-making; (e) will all disclosure statements in (c) be made publicly available and, if so, when, and, if not, why not; (f) which, if any, of the SEWG’s members have been trained in Dr. Zamboni’s methods and by whom were these members trained; (g) which, if any, of the SEWG’s members have watched diagnosis and treatment of CCSVI and, for each member identified (i) where did this observation take place, (ii) under what guidance, (iii) how many images and treatments were studied by the member; (h) which, if any, of the SEWG’s members have undertaken diagnosis and treatment of CCSVI and, for each member identified, (i) where were these actions performed, (ii) under what guidance, (iii) how many images and treatments were performed by the member; (i) does the CIHR recognize the emerging scientific discipline of neurovascular disease; (j) does the SEWG include any members of the International Society for NeuroVascular Disease (ISNVD) and, if so, who are these members, and, if not, why not; (k) which, if any, members of the SEWG have attended any of the ISNVD’s conferences, specifying for each such member the conferences that he or she attended; (l) does the inclusion of investigators of the seven MS Society-funded studies in the SEWG comply with the CIHR’s operating definition of “conflict of interest” and, if so, what are the reasons that explain this compliance; (m) regarding the “knowledge synthesis review”, (i) what is the protocol for the review, (ii) how is research deemed to be, or not to be, pertinent, (iii) who specifically is undertaking the review, how were they chosen, and what expertise do they have to undertake the review, (iv) why has the CIHR decided to have them undertake the review, (v) what are the CIHR’s reasons for not having the SEWG undertake the review, (vi) what is the cost of the review, (vii) what is a comprehensive list of abstracts to be reviewed, (viii) what additional material, people, or other sources will be consulted, (ix) will the review include scientific evidence presented at all the major scientific conferences on CCSVI to date, namely, Hamilton (February 2010), New York (July 2010), Washington (October 2010), Katowice (March 2011), Bologna (March 2011), Chicago (April 2011), and San Diego (May 2011), (x) will the review include contacting the leading experts in the field, asking for their unpublished data, visiting their laboratories and operating theatres, (xi) if the answer to (m)(x) is in the affirmative, what, if any, protocol has been established for each contact, and what, if any, weighting will be applied to this evidence; (n) how does the CIHR plan to weigh or asses the seven MS Society-funded studies and the “knowledge synthesis review” in its establishment of any future policy, particularly in its deliberations on whether to undertake clinical trials for CCSVI in Canada; (o) which , if any, members of the SEWG have attended any CCSVI conferences, specifying for each such member (i) what conferences he or she attended, (ii) in what capacity, (iii) who paid for the trip or attendance at the conference, (iv) what written evidence did he or she report to either the CIHR or SEWG, (v) if no written evidence was reported, why not; (p) which members of the CIHR have attended any CCSVI conferences, specifying for each such member (i) what conferences he or she attended, (ii) in what capacity, (iii) who paid for the trip or attendance at the conference, (iv) what written evidence he/she reported to either the CIHR or SEWG, (v) if no written evidence was reported, why not; (q) why has the CIHR decided not to further investigate CCSVI through clinical trials; (r) why has the CIHR decided not to follow recommendations made by the Ontario Association of Neurologists, the Canadian Society of Radiologists, the Canadian Society of Vascular Surgery, the American Society of Interventional Radiology, and the International Union of Phlebology regarding CCSVI; (s) what does the CIHR consider an “appropriate pace”, a term used in its May 18, 2011, e-mail to Dr. Kirsty Duncan, Member of Parliament for Etobicoke North, for the introduction to Canada of any potential new medical treatment for any medical condition, and how much evidence does the CIHR consider is required before a treatment should undergo clinical trials in Canada in terms of (i) the number of procedures undertaken, (ii) the number of countries undertaking the procedure, (iii) scientific evidence presented in academic peer-reviewed journals, (iv) scientific evidence presented at academic conferences, (v) scientific evidence presented at academic conferences for conditions that are progressive diseases, especially progressive diseases for which there are limited or no options for treatment; (t) what is the CIHR’s accepted protocol, including all necessary steps, for bringing a new treatment to clinical trials in Canada, (i) when was the protocol established, (ii) what treatments have undergone clinical trials as a result of the protocol, (iii) which treatments have been rejected to date; (u) is the creation of a SEWG a standard step in the CIHR’s protocol for bringing a new treatment to clinical trials in Canada, and, (i) if so, since the creation of the protocol, what are all new treatments and their associated SEWGs, (ii) if not, why was this step deemed necessary for approval of clinical trials for CCSVI; (v) what are the last five medical treatments for any medical condition accepted by the CIHR for use in Canada and, for each treatment, what are the details of all evidence required by the CIHR in its decision to have the treatment undergo clinical trials, including, but not limited to, the number of procedures undertaken, the countries undertaking the procedure, and scientific evidence presented in both peer-reviewed journals and academic conferences; and (w) with regard to the MS registry announced March 23, 2011, (i) who specifically is collecting the information, (ii) what precise information is being collected, (iii) what consent will be necessary from patients for any data collection, (iv) when will information begin to be collected, (v) what specific information is being collected regarding the treatment of CCSVI, (vi) what information is being gathered or tracking is being done of individuals who have chosen to have the liberation procedure outside Canada?
Historical information
The information shown below relates to a prior session.

Q-562

41-1
June 2, 2011, to September 13, 2013

Q-562

41st Parliament, 1st session
Asked by
Date asked
March 28, 2012
Answered
May 10, 2012
With respect to clinical trials for chronic cerebrospinal venous insufficiency (CCSVI): (a) what was the deadline for receiving applications for clinical trials for CCSVI and has the application process closed; (b) how many applications were received, and, for each application received, (i) from what institution and country was it received, (ii) are the researchers who submitted the application practiced in the diagnosis and treatment of CCSVI; (c) why was it decided that an international review panel was needed to assess applications for clinical trials; (d) what was the specific process for and who was involved in choosing the members of the international review panel; (e) who had the ultimate decision-making authority on the appointments to the international review panel; (f) has the international review panel been chosen, and, if so, (i) who is on the panel, (ii) why was each member chosen, (iii) for each member, is he or she practiced in the diagnosis and treatment of CCSVI; (g) how will all potential conflicts of interest of members of the international review panel be (i) recorded, (ii) confirmed, (iii) publicly declared; (h) has the review process of applications begun, (i) is it in progress, (ii) by what date is the review expected to be finished; (i) what specific criteria have been established to review applications; (j) by what date is an announcement expected to be made regarding the chosen research team or teams; (k) what, if any, monies have been set aside for clinical trials, (i) how was the required amount of money decided, (ii) will the monies allow for an adequate number of patients to be included to demonstrate clinical efficacy at the 0.05 level of significance; (l) what timeline is being allowed for ethics approval; (m) by what date is patient accrual expected to take place; (n) by what date are clinical trials expected to commence; and (o) what is a detailed timeline of what can be expected over the next year in terms of significant dates for clinical trials, as well as any dates for meetings regarding CCSVI?
Historical information
The information shown below relates to a prior session.

Q-729

41-1
June 2, 2011, to September 13, 2013

Q-729

41st Parliament, 1st session
Asked by
Date asked
June 11, 2012
Answered
September 17, 2012
With respect to the regulatory requirements for off-label use of a medical device and the special access program: (a) what are the federal regulations that control off-label use of a medical device already approved in Canada; (b) when a device such as a "stent" is proposed to be used by a licensed Canadian surgeon or interventional radiologist for the treatment of a medical condition not originally approved by the Medical Devices Bureau, (i) is there a requirement for a separate set of clinical trials or does such use fall under provincial jurisdiction and their practice of medicine guidelines, (ii) and if off-label use falls under provincial jurisdiction, why did the federal government intervene regarding the new procedure for chronic cerebrospinal venous insufficiency (CCSVI); (c) what are the regulatory requirements for the special access program that allows practitioners to request access to drugs or devices that are not currently approved for use in Canada for patients with serious or life threatening conditions, (i) why did the procedure for chronic CCSVI fail to meet the specified requirements on a compassionate or emergency basis when conventional therapies have failed, are unsuitable, or are unavailable, (ii) how did kidney denervation meet the specified requirements; (d) how many CCSVI procedures worldwide have been performed to date, (i) how many positive and negative peer-reviewed CCSVI studies have been published to date, (ii) how many Canadians are estimated to have had the procedure for CCSVI since January 2010, and how many of them have been followed to date, (iii) how many phase II and phase III clinical trials for CCSVI are currently underway internationally, (iv) in light of the safety findings reported on 1375 patients studied in eight recently published clinical trials on CCSVI, why is Canada beginning with a phase I study; and (e) how many procedures worldwide have been performed for kidney denervation, (i) how many positive and negative peer reviewed studies have been published to date, (ii) had the procedure been assessed through a double-blind trial with a placebo group when the procedure was approved in Canada, (iii) how many safety studies have been published to date, and what is the complication rate, (iv) what phase clinical trials are currently underway internationally, (v) will Canada be undertaking phased clinical trials?
Historical information
The information shown below relates to a prior session.

Q-1123

41-1
June 2, 2011, to September 13, 2013

Q-1123

41st Parliament, 1st session
Asked by
Date asked
December 11, 2012
Answered
March 8, 2013
With respect to the government’s position on chronic cerebrospinal venous insufficiency (CCSVI): (a) does the government track clinical trials on CCSVI currently being undertaken by other countries and, if yes, what are all clinical trials, identified by phase, currently being undertaken worldwide, (i) which countries are undertaking Phase lll trials; (b) does the government question whether CCSVI exists and, if yes, (i) why does the government not question whether treating CCSVI actually improves quality of life for Canadians with multiple sclerosis (MS); (c) how many cases of "major complications associated with venous angioplasty" have occurred in Canada and, if it is not possible to give this number, why, (i) what are identified complications to CCSVI and, for each complication, how many cases versus the number of procedures undertaken have occurred; (d) what are all procedures that have been performed on veins in Canada, including, procedures for Budd-Chiari syndrome and May-Thurner syndrome; (e) what is the government's position on ballooning veins and why does it consider that ballooning veins even once could be unsafe on fragile veins, even though participants involved in the proposed clinical trial will experience two procedures-one real, one simulated-in a one-year period; (f) is the government consulting with Canadians with MS, if so, (i) provide a list of all CCSVI groups the Minister of Health has met with along with the dates of the meetings, (ii) provide a list of all MS groups the Minister of Health has met with along with the dates of the meetings, (iii) provide the number of Canadians with MS the Minister of Health has met and the dates of all meetings, and if the government is not consulting, (iv) why not; (g) how does inviting the investigators of the seven MS-funded CCSVI studies to participate in the consensus workshop on ultrasound imaging meet CIHR's conflict of interest guidelines; (h) what were the results of the consensus workshop on ultrasound imaging, and specifically, (i) what exact imaging procedure will be used in the clinical trials, (ii) will the investigators use Dr Zamboni's procedure and, if so, will they be trained by Dr Zamboni, (iii) will the investigators use multi-modal imaging and, if so, what techniques, (iv) what training will investigators undergo, by whom, what is the number of procedures they will have to perform, and how will “sufficiently practiced” be ensured; (i) approximately how many Canadians with MS have died since November 2009, and by what EDSS score will Canadians with MS have worsened, on average by, since the same time period, and specifically, (i) how many are diagnosed each month, (ii) how many die each month; (j) when will patient accrual actually begin for clinical trials which were to begin on November 1st; and (k) what, if any, research or investment has been undertaken to consider whether to investigate the handling of the CCSVI file, particularly in relation to the "fast-tracking" of a new procedure in Canada, and the down-loading of services to provinces, (i) what are the dates, results and recommendations of any research, (ii) the dollar amount of any investment, (iii) if results and recommendations are available, will Health Canada be acting upon them and when?
Historical information
The information shown below relates to a prior session. The government is no longer required to respond to this question.

Q-1461

41-1
June 2, 2011, to September 13, 2013

Q-1461

41st Parliament, 1st session
Asked by
Date asked
September 12, 2013
Awaiting response
N/A
With respect to the chronic cerebrospinal venous insufficiency (CCSVI) clinical trial being undertaken by Dr. Traboulse: (a) what milestones are reportable to the government, (i) on what date(s) is reporting expected to occur, (ii) how will this information be communicated to patients, the medical community, and the general public; (b) on what date did each of the trial sites pass ethical review; (c) on what date did recruitment of patients begin for each of the trial sites; (d) how many patients with multiple sclerosis (MS) are being recruited for each site, and how is consistency in diagnosis and treatment being ensured across sites; (e) who is performing the diagnoses for CCSVI for each site, (i) how is the diagnosis being performed, including, but not limited to, ultrasound and venogram, (ii) how many diagnoses has each person undertaking the diagnosis at each site performed prior to the study, and by whom was each person trained; (f) who is performing the procedures for each site, (i) how is the procedure being performed, including, but not limited to, anesthetic, balloon size, (ii) how many procedures has each person undertaking the procedure at each site performed prior to the study, and by whom was each person trained; (g) what are the selection criteria for the trial, including, but not limited to, type of MS, Expanded Disability Status Scale (EDSS) score, venous abnormality/malformed valve/stenosis, mobility, (i) how do these criteria compare with the international literature, (ii) with how many international studies to date will the selection criteria be analytically comparable; (h) if both progressive and relapsing-remitting forms of MS are to be examined in the trial, how will statistical significance be ensured given that 50 of 100 patients will undergo a “sham” procedure, 25 patients will have a progressive form of the disease, and 25 will have a relapsing-remitting form of the disease, and will people with both primary progressive and secondary progressive forms of the disease be included, and if so, how will statistical significance be ensured; (i) given that research has shown numerous venous abnormalities in the head, neck, and chest of MS patients, (i) how will statistical significance be ensured if there are only a limited number of patients, but multiple types of venous or valvular abnormality, (ii) how will a venous stenosis be measured (e.g. diameter, size); (j) what outcomes will be measured, including, but not limited to, EDSS, Modified Fatigue Impact Scale (MFIS), Multiple Sclerosis Impact Scale (MSIS), and Multiple Sclerosis Quality of Life Inventory (MSQLI), and at what time scales; (k) will patient-reported quality of life scores be included, and if so, what is the specific methodology; (l) what specific follow-up care will patients undergoing the “sham” procedure and treatment receive, and at what specific time periods; (m) if patients received the “sham” procedure, within what time period will they receive treatment; (n) how will the results of this study be interpreted within the growing international body of research, (i) to how many studies will this study be compared, (ii) to how many studies will this study be directly comparable; (o) what long-term follow-up will those enrolled in the trial receive and for what time period; (p) what is the cost of the trial, and what are each of the partners contributing, including, but not limited to funding, equipment, expertise, pharmaceutical products; (q) what is the cost of each diagnosis, (i) what is the cost of each “sham” procedure, (ii) what is the cost of each procedure; and (r) who is overseeing the trial, (i) the safety of the patients, (ii) the integrity of the results?
Historical information
The information shown below relates to a prior session.

Q-264

41-1
June 2, 2011, to September 13, 2013

Q-264

41st Parliament, 1st session
Asked by
Date asked
November 30, 2011
Answered
January 30, 2012
With respect to the planning for and the execution of the joint meeting of the Canadian Institutes for Health Research (CIHR) and the Multiple Sclerosis Society of Canada (MSSC), on August 26, 2010: (a) what were the most recent statistics CIHR had regarding MS as of August 26, 2010, and had CIHR received, internally or externally, any request to update the figures beforehand; (b) what criteria were used to identify which international experts in chronic cerebrospinal venous insufficiency (CCSVI) should be invited to the August 26, 2010, meeting, and, (i) was Dr. Mark Haacke a candidate for invitation and, if so, why was he not invited, (ii) was Dr. Marion Simka a candidate for invitation and, if so, why was he not invited, (iii) was Dr. Paolo Zamboni a candidate for invitation, and, if so, why was he not invited, (iv) which invitees had expertise or experience administering CCSVI treatment, (v) why did the criteria not exclude from participation individuals who had publicly criticized the validity of CCSVI, (vi) what was the rationale for “[keeping] the international participation in focus” (Answer to Access to Information Request ATI 2010-006); (c) what CIHR experts were consulted regarding CCSVI/MS prior to the August 26, 2010, meeting, and, if any CIHR experts were consulted, what recommendations did they make, including any recommendations concerning large multi-centre clinical trials; (d) what briefings did the Minister of Health provide to members of the Conservative caucus regarding CCSVI or MS prior to the August 26, 2010, meeting, (i) what were the dates of any briefings, (ii) what information was provided; (e) did provincial governments express “mounting pressure” (ATI 2010-006) from the public regarding the need for clinical trials and treatment for CCSVI, and, if so, which provinces expressed any such pressure; (f) did any of the provinces and territories communicate an interest in partnering with the federal government on a “potential initiative” (ATI 2010-006), and, if so, what were the details of the “potential initiative” (ATI 2010-006); (g) by what date and by whom was CIHR made aware of the history of the theory of abnormal vasculature in MS dating back more than 100 years; (h) what was CIHR’s rationale for focussing its literature review on CCSVI and for excluding from consideration literature on the theory of abnormal vasculature in MS and why did CIHR decide to have students work on this literature review; (i) what criteria did the CIHR use to determine which of the 19 studies identified through PubMed (July 2010) it would include in its review of existing literature and research; (j) on what date did the President of CIHR first state that he would be pleased to provide for a randomized control trial on CCSVI treatment for review at the next grant competition, and (i) did the President ever speak to the “F/P/T” (ATI 2010-006) regarding the need for randomized clinical trials; (k) what lobbyists and/or pharmaceutical companies asked for a meeting with the Minister of Health’s office prior to August 26, 2010, to discuss a new oral MS drug and CCSVI treatment, and (i) what lobbyists and/or companies were “well respected” (ATI 2010-006) and had “a solid reputation with the MSSC” (ATI 2010-006); (l) why did CIHR change its position in March 2011 regarding an MS registry, and how was this change possible, given CIHR’s previous statements to Dr. Carolyn Bennett and Dr. Kirsty Duncan that the creation of such a registry “was outside” their “mandate” (ATI 2010-006); (m) did CIHR have money available for funding clinical trials related to CCSVI, (i) was CIHR “overcommitted” (ATI 2010-006), (ii) if so, by how much, (iii) could CIHR have found “some money” (ATI 2010-006), (iv) when could money have been available; (n) prior to the August 26, 2010, meeting, how many provinces and territories “expressed some level of support for a clinical trial” (ATI 2010-006); (o) concerning the e-mail exchange of August 24, 2011, contained in the response to ATI 2010-006, did the Minister of Health "have authority or [did] she need to go through cabinet" (ATI 2010-006); (p) were abnormal veins discussed in any of the August 26, 2010, presentations, and, if so, (i) which presenters covered this issue, (ii) what historical papers were referenced; (q) was iron accumulation in MS brains discussed in any of the August 26, 2010, presentations, and, if so, (i) which presenters covered the issue, (ii) what historical papers were referenced; (r) did any of the presentations explore a possible relationship between abnormal brain veins and tissue damage in MS, and, if so, (i) which presenters covered the issue, (ii) what historical papers were referenced; (s) what criteria were used or what process was followed to prepare the Summary Report of the August 26, 2010, meeting and, specifically, why was no reference made in the Summary Report to historical papers discussing abnormal vasculature and iron accumulation; and (t) does the Summary Report of the August 26, 2010, meeting disclose potential conflicts of interests of the attendees, and, if not, why was this information not included?
Historical information
The information shown below relates to a prior session.

Q-874

41-1
June 2, 2011, to September 13, 2013

Q-874

41st Parliament, 1st session
Asked by
Date asked
September 17, 2012
Answered
November 1, 2012
With regard to the Canadian Institutes of Health Research’s Scientific Expert Working Group: (a) was the Scientific Expert Working Group aware that on December 7th, 2010, Dr. Beaudet assured the Subcommittee on Neurological Disease that “no physician will refuse to see and treat them for complications of a treatment received abroad”; (b) why did the Scientific Expert Working Group state that “media reports that have stated that Multiple Sclerosis (MS) patients who experience complications after Chronic Cerebrospinal Venous Insufficiency (CCSVI) treatment are not being seen by Canadian doctors are not justified”, (i) what patients or patient advocacy groups were interviewed, (ii) what evidence was reviewed, (iii) what action was taken; (c) which of the provincial guidelines for follow up care does the Scientific Expert Working Group support; (d) what was the action undertaken by the government to ensure that all patients receive follow-up care, including patients suffering from complications from CCSVI treatments received abroad; (e) when was the Sub-Committee of the Scientific Expert Working Group formed, (i) why was it formed, (ii) who are the members of the sub-committee, (iii) what prompted a meeting to develop criteria for a recommendation for clinical trials on June 13th, 2011; (f) why did the Scientific Expert Working Group fail to sign a declaration of conflict of interest until June 2011; (g) what specific results were available from the seven MS Society of Canada-funded studies on June 28th 2011; (h) with respect to the Scientific Expert Working Group’s consensus workshop on ultrasound imaging, (i) on what date did the meeting take place, (ii) who was in attendance, (iii) what were the agenda items, (iv) what were the key recommendations, (v) why was Dr. Sandy McDonald not included, (vi) on what items did the group come to consensus; (i) what is the budget for the Scientific Expert Working Group specifically, (i) the monies allotted for 2010-2011, (ii) 2011-2012, (iii) the monies allocated for travel, (iv) the monies allocated for accommodation, (v) why was Agreement no 1148 to be signed at the end of February 2011 for monies that were to be available for 2010-2011; (j) with respect to Agreement no 1148 to support the Scientific Expert Working Group between the CIHR and the MS Society of Canada, (i) was the agreement ever signed and, if so (i) on what date, (ii) who made the grant application for the President’s Fund and on what date, (iii) what was the grant specifically for, (iv) why is the MS Society of Canada responsible for planning, support and implementation of the Scientific Expert Working Group, (v) what action is being taken to ensure that there are no conflicts of interest; (k) how many researchers/research groups applied for the Phase 1/11 clinical trial, and from what institutions; and (l) what has caused the delay in announcing the research team which was to be named by mid-April 2012?
Historical information
The information shown below relates to a prior session. The government is no longer required to respond to this question.

Q-1406

41-1
June 2, 2011, to September 13, 2013

Q-1406

41st Parliament, 1st session
Asked by
Date asked
June 6, 2013
Awaiting response
N/A
With regard to the Minister of Health’s signed response to Order Paper Question Q-1254: (a) how does the Minister and her government define “transparency”; (b) what does the Minister mean by "this Government has been as transparent as possible with parliamentarians and the public on this issue"; (c ) how does taking 225 days to answer Q-1254 meet the Minister’s definition of transparency, (i) how does taking 225 days meet the statement that Ministers are accountable to Parliament, and that they “must answer all questions pertaining to your (sic) areas of responsibility”, as cited in “Accountable Government: A Guide for Ministers and Ministers of State”, (ii) what criteria were used to ensure transparency; (d) how does answering only sub-questions (a), (q) and (z) of Q-1254 meet (i) the Minister’s definition of transparency used in (a), (ii) the guidelines in “Accountable Government”, (iii) what criteria were used to ensure transparency; (e) how does partially answering sub-questions (b), (c), and (n) meet (i) the Minister’s definition of transparency used in (a), (ii) the guidelines in “Accountable Government”, (iii) what criteria were used to ensure transparency; (f) how does refusing to answer sub-questions (d) to (h), (j), (l) to (m), (r) to (s), (u) to (y), and (aa) meet (i) the Minister’s definition of transparency used in (a), (ii) the guidelines in “Accountable Government”, (iii) what criteria were used to ensure transparency; (g) why does the government not track by hours, cost, number of drafts, and persons who work on speeches, when it tracks projected costs to answer opposition MPs’ Order Paper questions; (h) who does the government consider to be “key partners” regarding chronic cerebrospinal venous insufficiency (CCSVI) procedure; (i) what are the main CCSVI stakeholders across the country, (i) which, if any, does the government consider a “key partner”, (ii) with which, if any, does the “government communicate on a regular basis”; (j) why does the Canadian Multiple Sclerosis (MS) Monitoring System, which “was ready to receive data as of September 2012”, not contain any submitted data, (i) what are the barriers to having submitted data, (ii) what, if anything, can be done to make the system operational and functional, including, but not limited to, increased political will, human resources, financial resources, or improved cooperation with stakeholders; (k) if new Statistics Canada data was published in September 2012 showing that the number of people living with multiple sclerosis in Canada is 93,500, (i) why did John Wright, President and CEO of the Canadian Institute for Health Information use the numbers 55,000 to 75,000 at the October 4th, 2012 hearings on Bill S-204; (l) regarding the September 6, 2011, consensus workshop to determine the best procedures to standardize imaging of veins in the neck and brain, (i) who were the invited experts, (ii) how many imaging procedures for CCSVI had each expert undertaken, (iii) by whom were each of the experts trained, (iv) how many of the experts were funded by the Canadian Institutes for Health Research (CIHR); (m) what was the funding by each of CIHR, the MS Society of Canada, and the provinces of British Columbia, Manitoba, and Quebec for the $6 million CCSVI clinical trial; (n) which of (a), (b), or (c) is the government’s position regarding follow-up care (a) "MS patients who have received a venous procedure abroad should be reassured that they will be continued to be cared for by their physicians and/or regular MS specialists as any other patients?" (ATIP), (b) follow-up care as an issue that is primarily the responsibility of provincial and territorial governments (ATIP) or (c) “the federal government has provided regular MS research updates to provincial and territorial jurisdictions, which have the responsibility to ensure that Canadians receive appropriate health treatments and follow-up care” (answer to Order Paper question Q-1254); (o) what recourse and resources do Canadians who have been treated for CCSVI have should they be denied follow-up care, as Roxanne Garland was; (p) has the government been informed of a preliminary study for CCSVI undertaken in British Columbia, and if so, what were the preliminary results; and (q) has the $6 million CCSVI clinical trial begun and if not, why not, and if so, (i) on what date did patient accrual begin in each of the provinces, (ii) how many patients have been recruited for the trial by province, (iii) how many CCSVI procedures have been undertaken by province?
Historical information
The information shown below relates to a prior session.

Q-1254

41-1
June 2, 2011, to September 13, 2013

Q-1254

41st Parliament, 1st session
Asked by
Date asked
March 21, 2013
Answered
May 8, 2013
With regard to access to information requests ATI 2012-005 and 2012-006 submitted by Ms. Kirsty Duncan, M.P., for which a response was sent on February 22, 2013: (a) on what date were the two submissions made and what was the timeframe for completing the response; (b) why were the two requests returned together, some parts featuring page numbers and others not; (c) how many updates have been received from the Canadian Chronic Cerebrospinal Venous Insufficiency (CCSVI) Systematic Review Group to date, (i) how many studies in total have met the criteria for inclusion in the review, (ii) why does the group not identify, for each complication, the number of cases per number of people treated, (iii) why does the government not provide, for each serious complication listed, the number of cases per population treated; (d) on what date was the request for proposals for the CCSVI trials first drafted, (i) how may drafts were undertaken and on what dates, (ii) how many people worked on these drafts, for how many hours, and at what average cost to taxpayers, (iii) on what date did the provincial and territorial Ministers of Health review the draft, (iv) what was the feedback provided; (e) why, on November 22, 2012, was the amount available for the CCSVI trials in the range of $3-5 million, (i) what is the significance of the expression "should we just fudge a number"; (f) how was the decision made to earmark $3 million for the CCSVI trials and on what date was the decision made; (g) on what date and at what time was the Request for Applications (RFA) announcement for clinical trials published on the Canadian Institute for Health Research (CIHR)'s website, (i) on what date and at what time was Bill C-280, An Act to establish a National Strategy for Chronic Cerebrospinal Venous Insufficiency (CCSVI), scheduled to be debated; (h) why was there a change by the President's office at CIHR that the commitment from the CIHR be $2 million with the balance to come from partners, i.e. the Multiple Sclerosis Society of Canada (MSSC) and ''relevant provinces and territories'', and what were the relevant provinces and territories referred to; (i) how many versions of the Multiple Sclerosis (MS) research update deck were produced and on what dates, (i) how many people worked on these drafts, for how many hours, and at what average cost to taxpayers, (ii) when was the final draft presented, and for what purpose; (j) how many government MPs has the Health Minister met with on the issue of CCSVI/MS since May 2010, and how many government MPs have the Minister's officials met with on the issue of CCSVI/MS since May 2010; (k) how many draft speeches were prepared for government MPs for Motion M-274, (i) how many versions of each speech were produced and on what dates, (ii) how many people worked on these drafts, for how many hours, and at what average cost to taxpayers, (iii) how many government MPs read these prepared speeches; (l) regarding the briefing note for Dr. Alain Beaudet`s meeting with Dr. Jeffrey Turnbull, President of the Canadian Medical Association (CMA) on December 21, 2010, why did a recommendation in the briefing note state "The possibility of the CMA producing a position statement regarding patient access to physicians for patients who have received the Zamboni procedure", and "The fact that CIHR would be willing to provide the CMA with any necessary support in order to produce this statement", when the Scientific Expert Working Group (SEWG) stated that, "media reports that have stated that Multiple Sclerosis (MS) patients who experience complications after Chronic Cerebrospinal Venous Insufficiency (CCSVI) treatment are not being seen by Canadian doctors are not justified"; (m) regarding the briefing note for Dr. Alain Beaudet's meeting with Paul Emile Cloutier, CEO of the CMA on January 31, 2012, which shows CMA President Haggie testified before a Senate committee on Dec 2, 2011, and a House committee on October 17, 2011, (i) did President Haggie bring up at either committee meeting CMA's lack of support for either bills C-280 or S-204, (ii) why was President Haggie unaware of the lack of follow-up care for MS patients treated for CCSVI when President Turnbull was made aware, (iii) why was there a hiatus in correspondence with the CMA, (iv) for how long was the hiatus, (v) when did the hiatus end; (n) regarding the MS-Societies' seven funded studies regarding CCSVI, why was there, at the 18-month mark, an inquiry into the training of the teams, (i) which of the teams were trained by Dr. Zamboni and which individual members of each team were trained by Dr. Zamboni, (ii) which of the teams were trained by Dr. Zivadinov and which individual members of each team were trained by Dr. Zivadinov, (iii) which teams were trained by neither or by another team; (o) how many people worked on drafts of prepared speeches for bill C-280, An Act to establish a National Strategy for Chronic Cerebrospinal Venous Insufficiency (CCSVI), for how many hours, and at what average cost to taxpayers and how many government MPs read these prepared speeches; (p) how many people worked on drafts of prepared speeches for bill S-204, An Act to establish a National Strategy for Chronic Cerebrospinal Venous Insufficiency (CCSVI), for how many hours, and at what average cost to taxpayers, (i) how many government Senators read these prepared speeches; (q) on what dates was the Canadian MS Monitoring System to be ready to receive data and when did the system start collecting data; (r) is the government's position regarding MS patients’ input into the Scientific Expert Working Group (SEWG) in accordance with the statement "CIHR's Scientific Expert Working Group includes researchers with expertise in different disciplines such as neurology, vascular surgery and vascular imaging who are treating MS patients and who will be bringing their patients' concerns to the table" (ATIP); (s) is it still the government's position that "Benoit's motion speaks far more to PHAC's monitoring system than anything we are doing on the trials front" (ATIP); (t) how many draft MS slide decks were prepared for Senatorial Caucus, (i) how many versions of each deck were produced and on what dates, (ii) how many people worked on these drafts, for how many hours, and at what average cost to taxpayers, (iii) who presented the deck to the Senatorial Caucus; (u) is the government's position as per the information sheet provided when Dr. Alain Beaudet wrote to the Colleges of Physicians on February 29, 2012 which says, "MS patients who have received a venous procedure abroad should be reassured that they will be continued to be cared for by their physicians and/or regular MS specialists as any other patients?” or is it that follow-up care is primarily the responsibility of provincial and territorial governments to ensure that no Canadian is denied post-treatment and follow-up care (ATIP) and what role does the federal government have if patients are being denied follow-up care by a province or territory; (v) why did the government ask the Multiple Sclerosis Society of Canada (MSSC) on February 7, 2012 about approved venous angioplasty; (w) is it still the government's position that the MS documentary that aired on the Nature of Things on February 9, 2012, was "balanced and fair"; (x) why does a February 16, 2012 e-mail list MS patients who are also CCSVI advocates; (y) is the government's position regarding imaging for CCSVI in accordance with the International Society for NeuroVascular Disease (ISNVD) venography statement and consensus document and, if not, why not; and (z) does the government know how many Canadians are actually impacted by MS, (i) if so, what is the number, (ii) if not, why not; and (aa) when Dr. Alain Beaudet wrote to the Colleges of Physicians on February 29, 2012, (i) why was the list of 11 recent peer-reviewed publications provided not a comprehensive list, (i) why did the list not specify what were positive and negative studies, and what imaging techniques were used, (ii) for MS patients who are denied follow-up care, what recourse and resources do they have, (iii) what is the position of the Scientific Expert Working Group concerning MS patients who have been denied follow-up care, such as Roxanne Garland?
Top of page